In today’s session Akorn, Inc. (AKRX) registered an unusually high (1,012) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the November, 2016 call, expecting serious AKRX increase. With 1,012 contracts traded and 4664 open interest for the Nov, 16 contract, it seems this is a quite bullish bet. The option with symbol: AKRX161118C00027500 closed last at: $0.65 or 30% up. About 2.08M shares traded hands or 92.59% up from the average. Akorn, Inc. (NASDAQ:AKRX) has risen 5.37% since April 1, 2016 and is uptrending. It has outperformed by 4.15% the S&P500.
Akorn, Inc. (NASDAQ:AKRX) Ratings Coverage
Out of 12 analysts covering Akorn Inc (NASDAQ:AKRX), 7 rate it a “Buy”, 0 “Sell”, while 5 “Hold”. This means 58% are positive. $48 is the highest target while $24 is the lowest. The $35.33 average target is 61.69% above today’s ($21.85) stock price. Akorn Inc has been the topic of 18 analyst reports since July 21, 2015 according to StockzIntelligence Inc. The firm has “Buy” rating given on Wednesday, December 2 by Nomura. The stock has “Market Perform” rating given by Leerink Swann on Wednesday, March 16. JP Morgan maintained the shares of AKRX in a report on Monday, March 14 with “Overweight” rating. The company was downgraded on Friday, August 5 by Deutsche Bank. The firm earned “Market Perform” rating on Wednesday, September 9 by JMP Securities. The company was maintained on Friday, February 12 by RBC Capital Markets. The rating was upgraded by Piperjaffray to “Overweight” on Thursday, September 15. The firm earned “Neutral” rating on Tuesday, September 29 by Nomura. The firm has “Neutral” rating by Susquehanna given on Wednesday, March 23. The stock of Akorn, Inc. (NASDAQ:AKRX) has “Buy” rating given on Wednesday, March 23 by Jefferies.
According to Zacks Investment Research, “Akorn, Inc. manufactures and markets diagnostic and therapeutic pharmaceuticals in specialty areas such as ophthalmology, rheumatology, anesthesia and antidotes, among others. They also market ophthalmic surgical instruments and related products. Customers include physicians, optometrists, wholesalers, group purchasing organizations and other pharmaceutical companies. They also provide contract manufacturing services.”
Akorn Inc., together with its subsidiaries, is a specialty pharmaceutical firm that develops, makes and markets generic and branded prescription pharmaceuticals, as well as private-label over-the-counter consumer health products and animal health pharmaceuticals. The company has a market cap of $2.85 billion. The Firm operates through two divisions: Prescription Pharmaceuticals and the Consumer Health. It has a 14.63 P/E ratio. The Prescription Pharmaceuticals segment is engaged in manufacturing and marketing generic and branded prescription pharmaceuticals, including ophthalmics, injectables, oral liquids, otics, topical, inhalants and nasal sprays.
AKRX Company Profile
Akorn Inc. (Akorn), incorporated on January 20, 1971, together with its subsidiaries, is a specialty pharmaceutical firm that develops, makes and markets generic and branded prescription pharmaceuticals, as well as private-label over-the-counter (OTC) consumer health products and animal health pharmaceuticals. The Firm operates through two divisions: Prescription Pharmaceuticals and the Consumer Health. The Firm is engaged in the development, manufacturing and marketing of generic pharmaceutical products in alternative dosage forms. It is focused on sterile and non-sterile dosage forms including, ophthalmics, injectables, oral liquids, otics, topicals, inhalants and nasal sprays. The Company’s Akorn Consumer Health division (ACH) markets a portfolio of OTC brands and various formulations of private-label OTC pharmaceutical products. The Company’s OTC brand is TheraTears Therapy for Your Eyes, which is a family of therapeutic eye care products, including dry eye therapy lubricating eye drops, eyelid and eyelash cleansing foam and eye nutrition supplements.
More news for Akorn, Inc. (NASDAQ:AKRX) were recently published by: Digitaljournal.com, which released: “Investigation for Investors in Shares of Akorn, Inc. (NASDAQ:AKRX) over …” on November 03, 2016. Businesswire.com‘s article titled: “Robbins Arroyo LLP: Akorn, Inc. (AKRX) Misled Shareholders According to a …” and published on October 28, 2016 is yet another important article.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.